🔗 Share this article

The recently developed medications for gonorrhoea in decades are being hailed as a "huge turning point" in the battle against superbug strains of the infection, according to scientists.

An International Health Concern

The sexually transmitted infection are increasing worldwide, with estimates suggesting more than 82 million infections each year. Especially elevated rates are observed in the African continent and nations within the World Health Organization's designated area, which includes Mongolia and China to New Zealand. In England, cases have hit a historical peak, while rates across Europe in 2023 were three times higher compared to figures for 2014.

“The approval of fresh medications for gonorrhoea is an significant and necessary step in the context of growing infection rates, escalating drug resistance and the very limited available drugs presently on offer.”

Medical experts are increasingly worried about the rise in antibiotic-resistant strains. The global health body has listed it as a "critical concern". Recent surveillance showed that the effectiveness of primary antibiotics like ceftriaxone and cefixime increased dramatically between 2022 and 2024.

A Pair of Novel Drugs Receive Clearance

One new antibiotic, marketed under the name a brand name, was cleared by the US Food and Drug Administration in mid-December for treating gonorrhoea. This STI can lead to significant complications, including the inability to conceive. Researchers hope that targeted use of this new drug will help hinder the emergence of superbugs.

Gepotidacin, created by the drugmaker GlaxoSmithKline, was also approved in close succession. This medication, which is also used to treat UTIs, was demonstrated in studies to be successful in treating superbug versions of the gonorrhoea bacteria.

A Novel Approach to Creation

This new treatment emerged from a innovative non-profit model for antibiotic development. The charitable organization GARDP partnered with the drug firm Innoviva to bring it to fruition.

“This approval signifies a major breakthrough in the management of multidrug-resistant gonorrhoea, which up to this point has been evolving faster than medical innovation.”

Testing Results and Worldwide Availability

Based on data released by a prominent scientific publication, zoliflodacin successfully treated the vast majority of cases of the STI. This puts it on an comparable level with the existing first-line therapy, which involves an injection and a pill. The trial involved over 900 patients from various regions including Belgium, the Netherlands, South Africa, Thailand and the US.

Through the arrangement of its collaboration, the non-profit has the authority to make available and distribute the drug in numerous low-income and middle-income countries.

Medical professionals treating patients have shared positive views. The availability of a one-pill regimen of this kind is described as a "critical tool" for managing the epidemic. This is viewed as essential to lessen the impact of the infection for individuals and to halt the transmission of untreatable gonorrhoea globally.